PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
Main Authors: | G. Tsykunova, P. A. Holme, H. Thi Thyuet Tran, T. H. A. Tvedt, L. Munthe, M. Michel, H. Frederiksen, J. Bussel, D. Kuter, W. Ghanima |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000852076.33574.89 |
Similar Items
-
2313
by: Nikhil Satchidanand, et al.
Published: (2017-09-01) -
PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
by: Elena Vaneeva, et al.
Published: (2023-08-01) -
2313 Characterization of the host pericyte role in glioblastoma angiogenesis
by: Frank Attenello, et al.
Published: (2018-06-01) -
PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY
by: A. Åkesson, et al.
Published: (2022-06-01) -
S293: RISK OF FRACTURES IN ADULT PATIENTS WITH PRIMARY AND SECONDARY IMMUNE THROMBOCYTOPENIA: A DANISH NATIONWIDE COHORT STUDY
by: N. Mannering, et al.
Published: (2022-06-01)